Details of the Drug Combinations

General Information of This Drug (ID: DMIYDT4)

• Drug Name: Cabozantinib (DMIYDT4)
• Synonyms: Cabometyx; Cometriq

Indication

Medullary thyroid gland carcinoma; ICD 11: N.A.; Status: Approved [1]; Thyroid cancer; ICD 11: 2D10; Status: Approved [2]; Ovarian cancer; ICD 11: 2C73; Status: Phase 2 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

9 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AXL-1717 + Cabozantinib	DCXBF4X	AXL-1717	Ewing sarcoma (Cell Line: TC-71)	[3]
AXL-1717 + Cabozantinib	DC87RAR	AXL-1717	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
Cabozantinib + Buparlisib	DCH8AAI	Buparlisib	Ewing sarcoma (Cell Line: TC-71)	[3]
Cabozantinib + AZD8055	DCYH5NW	AZD8055	Ewing sarcoma (Cell Line: TC-71)	[3]
Cabozantinib + Formononetin	DCQJZSY	Formononetin	Ewing sarcoma (Cell Line: TC-71)	[3]
Cabozantinib + Idarubicin	DC27LYP	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]
Cabozantinib + Formononetin	DCX18PG	Formononetin	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
Cantharidin + Cabozantinib	DC8FXHY	Cantharidin	Ewing sarcoma (Cell Line: TC-71)	[3]
Docetaxel + Cabozantinib	DCWIRRJ	Docetaxel	Ewing sarcoma (Cell Line: TC-71)	[3]

19 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABIRATERONE + Cabozantinib	DC7GQU9	ABIRATERONE	Prostate Cancer	[5]
Cabozantinib + Temozolomide	DC0XXGT	Temozolomide	Glioblastoma	[6]
Cabozantinib + Pemetrexed	DC4EQRP	Pemetrexed	Non Small Cell Lung Cancer	[7]
Cabozantinib + Lutetium Lu 177 dotatate	DC8UNM0	Lutetium Lu 177 dotatate	Neuroendocrine Tumors	[8]
Erlotinib + Cabozantinib	DC6Z0ZX	Erlotinib	Carcinoma, Non-Small-Cell Lung	[9]
Fulvestrant + Cabozantinib	DCMHKI2	Fulvestrant	Breast Cancer	[10]
Gemcitabine + Cabozantinib	DCHGWKZ	Gemcitabine	Pancreatic Cancer	[11]
Isotretinoin + Cabozantinib	DCR3V1M	Isotretinoin	Solid Tumor	[12]
Lenvatinib + Cabozantinib	DCSRGUI	Lenvatinib	Differentiated Thyroid Gland Carcinoma	[13]
Rosiglitazone + Cabozantinib	DCTL892	Rosiglitazone	Papillary Thyroid Cancer	[14]
Vemurafenib + Cabozantinib	DCYAYKI	Vemurafenib	Recurrent Melanoma	[15]
Cabozantinib + Cabozantinib	DCYJ6Y9	Cabozantinib	Non Small Cell Lung Cancer	[16]
Cabozantinib + Vandetanib	DC6PJ87	Vandetanib	Thyroid Cancer	[17]
CB-839 + Cabozantinib	DCA8K1H	CB-839	Advanced Renal Cell Carcinoma	[18]
Erlotinib + Cabozantinib	DC2VT6E	Erlotinib	Pancreatic Adenocarcinoma Metastatic	[19]
Lanreotide acetate + Cabozantinib	DC2EEYD	Lanreotide acetate	Metastatic Well Differentiated Neuroendocrine Neoplasm	[20]
Regorafenib + Cabozantinib	DCY6J0F	Regorafenib	Non-small Cell Lung Carcinoma	[21]
Cabozantinib + Vandetanib	DCENZFR	Vandetanib	Medullary Thyroid Cancer	[22]
Sunitinib + Cabozantinib	DC7NJPE	Sunitinib	Renal Cell Carcinoma	[23]

References

• [1] Cabozantinib FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] ClinicalTrials.gov (NCT01574937) XL-184+Abiraterone in Post-Chemo CRPC
• [6] ClinicalTrials.gov (NCT00960492) Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
• [7] ClinicalTrials.gov (NCT04173338) Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
• [8] ClinicalTrials.gov (NCT05249114) Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
• [9] ClinicalTrials.gov (NCT00596648) A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
• [10] ClinicalTrials.gov (NCT01441947) Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
• [11] ClinicalTrials.gov (NCT01663272) A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
• [12] ClinicalTrials.gov (NCT03611595) Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
• [13] ClinicalTrials.gov (NCT02592356) Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
• [14] ClinicalTrials.gov (NCT01100619) A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
• [15] ClinicalTrials.gov (NCT01835184) Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
• [16] ClinicalTrials.gov (NCT04131543) Phase II Study With Cabozantinib in Patients With RET Positive NSCLC
• [17] ClinicalTrials.gov (NCT03630120) Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
• [18] ClinicalTrials.gov (NCT03428217) CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
• [19] ClinicalTrials.gov (NCT03213626) Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
• [20] ClinicalTrials.gov (NCT04427787) A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
• [21] ClinicalTrials.gov (NCT02795156) Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
• [22] ClinicalTrials.gov (NCT04760288) A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
• [23] ClinicalTrials.gov (NCT03729245) A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)